960 related articles for article (PubMed ID: 16338276)
1. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens.
von Richter O; Burk O; Fromm MF; Thon KP; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2004 Mar; 75(3):172-83. PubMed ID: 15001968
[TBL] [Abstract][Full Text] [Related]
3. 6',7'-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein.
Edwards DJ; Fitzsimmons ME; Schuetz EG; Yasuda K; Ducharme MP; Warbasse LH; Woster PM; Schuetz JD; Watkins P
Clin Pharmacol Ther; 1999 Mar; 65(3):237-44. PubMed ID: 10096255
[TBL] [Abstract][Full Text] [Related]
4. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man.
Kupferschmidt HH; Fattinger KE; Ha HR; Follath F; Krähenbühl S
Br J Clin Pharmacol; 1998 Apr; 45(4):355-9. PubMed ID: 9578182
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components.
Eagling VA; Profit L; Back DJ
Br J Clin Pharmacol; 1999 Oct; 48(4):543-52. PubMed ID: 10583025
[TBL] [Abstract][Full Text] [Related]
6. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression.
Lown KS; Bailey DG; Fontana RJ; Janardan SK; Adair CH; Fortlage LA; Brown MB; Guo W; Watkins PB
J Clin Invest; 1997 May; 99(10):2545-53. PubMed ID: 9153299
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression.
Pinto AG; Wang YH; Chalasani N; Skaar T; Kolwankar D; Gorski JC; Liangpunsakul S; Hamman MA; Arefayene M; Hall SD
Clin Pharmacol Ther; 2005 Mar; 77(3):178-88. PubMed ID: 15735612
[TBL] [Abstract][Full Text] [Related]
8. Lack of in vivo correlation between indinavir and saquinavir exposure and cytochrome P450 3A phenotype as assessed with oral midazolam as a phenotype probe.
Robertson SM; Formentini E; Alfaro RM; Falloon J; Penzak SR
Pharmacotherapy; 2006 Aug; 26(8):1051-9. PubMed ID: 16863481
[TBL] [Abstract][Full Text] [Related]
9. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.
Hu YF; Qiu W; Liu ZQ; Zhu LJ; Liu ZQ; Tu JH; Wang D; Li Z; He J; Zhong GP; Zhou G; Zhou HH
Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1093-8. PubMed ID: 17042920
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs.
Ieiri I; Tsunemitsu S; Maeda K; Ando Y; Izumi N; Kimura M; Yamane N; Okuzono T; Morishita M; Kotani N; Kanda E; Deguchi M; Matsuguma K; Matsuki S; Hirota T; Irie S; Kusuhara H; Sugiyama Y
J Clin Pharmacol; 2013 Jun; 53(6):654-61. PubMed ID: 23381882
[TBL] [Abstract][Full Text] [Related]
11. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
Shi XJ; Geng F; Jiao Z; Cui XY; Qiu XY; Zhong MK
J Clin Pharm Ther; 2011 Oct; 36(5):614-24. PubMed ID: 21916909
[TBL] [Abstract][Full Text] [Related]
12. Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal first-pass extraction of saquinavir.
Mouly SJ; Paine MF; Watkins PB
J Pharmacol Exp Ther; 2004 Mar; 308(3):941-8. PubMed ID: 14718607
[TBL] [Abstract][Full Text] [Related]
13. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.
Kuypers DR; de Jonge H; Naesens M; Lerut E; Verbeke K; Vanrenterghem Y
Clin Pharmacol Ther; 2007 Dec; 82(6):711-25. PubMed ID: 17495880
[TBL] [Abstract][Full Text] [Related]
14. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice.
Veronese ML; Gillen LP; Burke JP; Dorval EP; Hauck WW; Pequignot E; Waldman SA; Greenberg HE
J Clin Pharmacol; 2003 Aug; 43(8):831-9. PubMed ID: 12953340
[TBL] [Abstract][Full Text] [Related]
15. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
[TBL] [Abstract][Full Text] [Related]
16. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins.
Malhotra S; Bailey DG; Paine MF; Watkins PB
Clin Pharmacol Ther; 2001 Jan; 69(1):14-23. PubMed ID: 11180034
[TBL] [Abstract][Full Text] [Related]
17. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
18. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation.
Goto M; Masuda S; Saito H; Uemoto S; Kiuchi T; Tanaka K; Inui K
Pharmacogenetics; 2002 Aug; 12(6):451-7. PubMed ID: 12172213
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin.
Paine MF; Wagner DA; Hoffmaster KA; Watkins PB
Clin Pharmacol Ther; 2002 Nov; 72(5):524-35. PubMed ID: 12426516
[TBL] [Abstract][Full Text] [Related]
20. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients.
Yates CR; Zhang W; Song P; Li S; Gaber AO; Kotb M; Honaker MR; Alloway RR; Meibohm B
J Clin Pharmacol; 2003 Jun; 43(6):555-64. PubMed ID: 12817518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]